Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

Karina found her fit at Lilly through our summer internship program. She is now hoping to inspire more Latinx students to make changes in the STEM field just as her mentor did for her. Visit careers.lilly.com/LRL to find open roles in Lilly’s research labs. #WeAreLilly

893 S Delaware St
Indianapolis, IN 46285

Discovery is
in our DNA

Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.

Explore Careers

We are Lilly

Why do our employees love coming to work each and every day? Here’s what they have to say.

“Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”

Kavita - Associate Director, Packaging Operations
“Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”

Adrian - Associate Director, IDM
“What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”

Cecile - Sr Director, Design Hub Foundations

39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.

View Stories

NEWS

Pictured: Eli Lilly's headquarters in Indianapolis

Artificial intelligence

Lilly, Insitro Ink Unique AI Deal, Eye Novel Treatments for Metabolic Diseases

In a departure from most deals, startup insitro will in-license Lilly’s delivery technology for its investigational liver-targeted siRNA therapies. The pharma will be eligible for milestones and royalties down the line.

October 9, 2024

2 min read

Tristan Manalac

Podcast

BioSpace at Meeting on the Mesa, WuXi Considers Selling U.S. Facilities, Big Pharma Layoffs, More

Cell and gene therapy investment rebounds; WuXi Biologics and other companies named in BIOSECURE Act mull options; Bayer, J&J and Pfizer’s recent layoffs; updates from the weight loss space.

October 9, 2024

1 min read

Heather McKenzie

Leadership concept with chess figures. 3D Rendering

Obesity

Lilly’s Sprawling Obesity Clinical Program Underscores Challenges for Biotechs

Eli Lilly CEO David Ricks is confident his company and peer Novo Nordisk are years ahead in the weight loss space, as biotechs press on with compelling data.

October 9, 2024

3 min read

Annalee Armstrong

Banner. Contemporary art collage. Charity or alms. Person handing single coin to another person. Grainy fabric effect. Concept of business, financial literacy, debts, banking, salary. Ad

Deals

5 Radiopharma Biotechs to Watch for Potential Buyouts

Big Pharma can’t seem to get enough radiopharmaceutical biotechs. With Lilly, Sanofi and BMS chasing Novartis into the complex space, all eyes are on these specialty biotechs.

October 9, 2024

5 min read

Annalee Armstrong

Central Coast New South Wales Australia – May 21, 2024 Assortment of weight loss and diabetic drugs on the table

Editorial

Obesity Drug Shortage Ends for Lilly, Continues for Novo as Industry Bolsters Manufacturing

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the insatiable demand for weight loss drugs.

October 4, 2024

3 min read

Greg Slabodkin

Pictured: An Eli Lilly Research Laboratories sign/

Supply chain

Lilly’s Tirzepatide No Longer on FDA Drug Shortage List

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes and weight loss drugs are gaining market share as manufacturing continues to expand, while noting the drugmaker could start to benefit heading into third quarter earnings.

October 3, 2024

2 min read

Tristan Manalac

External view of Eli Lilly's world headquarters in Indianapolis

Manufacturing

Lilly to Invest $4.5B in New Indiana Manufacturing and R&D Center

Eli Lilly’s investment in the LEAP Research and Innovation District in Lebanon, Indiana, has now jumped to more than $13 billion.

October 2, 2024

2 min read

Tristan Manalac

Editorial

Lilly Is Not ‘Feeling the Bern’ on Drug Prices Like Novo: Why the Double Standard?

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s rival drugs, is not fair.

September 27, 2024

3 min read

Greg Slabodkin

Deals

Lilly and Novo Spend Billions to Expand Obesity Pipelines Beyond GLP-1s

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in licensing and M&A deals.

September 25, 2024

10 min read

Annalee Armstrong

JOBS